Tag: fgf21

Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
Health

Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH

89bio’s pegozafermin allows for a potentially best-in-disease treatment for moderate to severe…

GlobeNews Wire
GlobeNews Wire